BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-79@catalystbrief.girapphe.com
DTSTAMP:20261117T061555Z
LAST-MODIFIED:20261117T061555Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Readout: Madrigal Pharmaceuticals\, Inc. — Resmetirom [Mar 2027]
DESCRIPTION:Phase 3 primary completion: A Phase 3 Study to Evaluate Safety 
 and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fat
 ty Liver Disease (NAFLD)\, MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAF
 LD-OLE).\nSource: https://clinicaltrials.gov/study/NCT04951219\nhttps://ca
 talystbrief.girapphe.com/e/79?lang=en\nNot investment advice. Dates may ch
 ange.
URL:https://catalystbrief.girapphe.com/e/79?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
